Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Akin

Showing results (131-140 of 203) with videos related to

Pageof 21
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 1, 2012
Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implicationsRussell J H Ryan, Cem Akin, Mariana Castells, et al.
Leukemia Research|June 27, 2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitSrdan Verstovsek, Cem Akin, Taghi Manshouri, et al.
European Journal of Haematology|December 19, 2015
Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease?Celalettin Ustun, Angela Smith, Zuzan Cayci, et al.
International Journal of Molecular Sciences|February 4, 2021
A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell DisordersJan Romantowski, Aleksandra Górska, Marek Niedoszytko, et al.
Orphanet Journal of Rare Diseases|March 25, 2023
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF<sup>©</sup>) and determination of a threshold score for moderate symptomsAlan L Shields, Fiona Taylor, Roger E Lamoureux, et al.
Orphanet Journal of Rare Diseases|October 10, 2021
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF<sup>©</sup>Fiona Taylor, Cem Akin, Roger E Lamoureux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.
Blood|August 17, 2006
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutationJingxuan Pan, Alfonso Quintás-Cardama, Hagop M Kantarjian, et al.
Haematologica|July 7, 2018
Preclinical human models and emerging therapeutics for advanced systemic mastocytosisMichel Arock, Ghaith Wedeh, Gregor Hoermann, et al.
Orphanet Journal of Rare Diseases|October 19, 2021
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical studyBrad Padilla, Alan L Shields, Fiona Taylor, et al.
Pageof 21

Showing results (131-140 of 203) with videos related to

Sort By:
Pageof 21
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 1, 2012
Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implicationsRussell J H Ryan, Cem Akin, Mariana Castells, et al.
Leukemia Research|June 27, 2006
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kitSrdan Verstovsek, Cem Akin, Taghi Manshouri, et al.
European Journal of Haematology|December 19, 2015
Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease?Celalettin Ustun, Angela Smith, Zuzan Cayci, et al.
International Journal of Molecular Sciences|February 4, 2021
A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell DisordersJan Romantowski, Aleksandra Górska, Marek Niedoszytko, et al.
Orphanet Journal of Rare Diseases|March 25, 2023
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF<sup>©</sup>) and determination of a threshold score for moderate symptomsAlan L Shields, Fiona Taylor, Roger E Lamoureux, et al.
Orphanet Journal of Rare Diseases|October 10, 2021
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF<sup>©</sup>Fiona Taylor, Cem Akin, Roger E Lamoureux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.
Blood|August 17, 2006
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutationJingxuan Pan, Alfonso Quintás-Cardama, Hagop M Kantarjian, et al.
Haematologica|July 7, 2018
Preclinical human models and emerging therapeutics for advanced systemic mastocytosisMichel Arock, Ghaith Wedeh, Gregor Hoermann, et al.
Orphanet Journal of Rare Diseases|October 19, 2021
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical studyBrad Padilla, Alan L Shields, Fiona Taylor, et al.
Pageof 21